Alzheimer’s disease market to reach $17 billion in 8MM by 2033

The Alzheimer’s disease (AD) market across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, Japan, and China) is forecast to expand from $2.4 billion in 2023 to $17.0 billion by 2033, at a compound annual growth rate (CAGR) of 21.8%.

The sector will be primarily driven by the entry of expensive disease-modifying therapies (DMTs) into the market, an aging global population leading to an increase in prevalent cases, and the launch of novel symptomatic therapies for the treatment of agitation and psychosis associated with AD, according to pharma analytics company GlobalData.

GlobalData’s latest report, “Alzheimer’s Disease: Eight-Market Drug Forecast and Market Analysis – Update,” reveals that DMTs, which will likely result in increased treatment rates as more options become available, are expected to dominate the global AD market, contributing 69.2% of the market by 2033, with drugs targeting amyloid beta (Aβ) making up the majority of this.